Ahn MJ - Search Results

1

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA. Yang JC, et al. Among authors: ahn mj. J Clin Oncol. 2017 Apr 20;35(12):1288-1296. doi: 10.1200/JCO.2016.70.3223. Epub 2017 Feb 21. J Clin Oncol. 2017. PMID: 28221867 Free article. Clinical Trial.

2

Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?

Ahn MJ, Park BB, Ahn JS, Kim SW, Kim HT, Lee JS, Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Ki CS, Park CK, Holmes AJ, Jänne PA, Park K. Ahn MJ, et al. Among authors: ahn js. Clin Cancer Res. 2008 Jun 15;14(12):3860-6. doi: 10.1158/1078-0432.CCR-07-4608. Clin Cancer Res. 2008. PMID: 18559606 Clinical Trial.

3

Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras.

Kim HS, Park K, Jun HJ, Yi SY, Lee J, Ahn JS, Park YH, Kim S, Lee S, Ahn MJ. Kim HS, et al. Among authors: ahn js, ahn mj. Oncology. 2009;76(4):239-46. doi: 10.1159/000205386. Epub 2009 Feb 25. Oncology. 2009. PMID: 19246948

4

Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer.

Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, Jänne PA, Ahn MJ. Park S, et al. Among authors: ahn js, ahn mj. J Thorac Oncol. 2009 Jul;4(7):809-15. doi: 10.1097/JTO.0b013e3181a94af4. J Thorac Oncol. 2009. PMID: 19487967 Free article.

5

Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.

Lee DH, Kim SW, Suh C, Lee JS, Ahn JS, Ahn MJ, Park K, Na II, Lee JC, Ryoo BY, Yang SH. Lee DH, et al. Among authors: ahn js, ahn mj. Cancer. 2010 Jan 1;116(1):132-6. doi: 10.1002/cncr.24719. Cancer. 2010. PMID: 19904804 Free article. Clinical Trial.

6

Randomized, multi-center phase II trial of docetaxel plus cisplatin versus etoposide plus cisplatin as the first-line therapy for patients with advanced non-small cell lung cancer.

Lee NS, Park HS, Won JH, Hong DS, Uh ST, Lee SJ, Kim JH, Kim SK, Ahn MJ, Choi JH, Yang SC, Lee JA, Lee KS, Yim CY, Lee YC, Kim CS, Lee MH, Jung KD, Moon H, Lee YS. Lee NS, et al. Among authors: ahn mj. Cancer Res Treat. 2005 Dec;37(6):332-8. doi: 10.4143/crt.2005.37.6.332. Epub 2005 Dec 31. Cancer Res Treat. 2005. PMID: 19956368 Free PMC article.

7

The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.

Chang MH, Ahn JS, Lee J, Kim KH, Park YH, Han J, Ahn MJ, Park K. Chang MH, et al. Among authors: ahn js, ahn mj. Lung Cancer. 2010 Sep;69(3):323-9. doi: 10.1016/j.lungcan.2009.12.002. Epub 2010 Jan 12. Lung Cancer. 2010. PMID: 20061047

8

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.

Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, Ahn MJ, Ahn JS, Suh C, Kim SW. Lee DH, et al. Among authors: ahn js, ahn mj. Clin Cancer Res. 2010 Feb 15;16(4):1307-14. doi: 10.1158/1078-0432.CCR-09-1903. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145166 Clinical Trial.

9

The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.

Sun JM, Won YW, Kim ST, Kim JH, Choi YL, Lee J, Park YH, Ahn JS, Park K, Ahn MJ. Sun JM, et al. Among authors: ahn js, ahn mj. J Cancer Res Clin Oncol. 2011 Apr;137(4):687-94. doi: 10.1007/s00432-010-0928-2. Epub 2010 Jun 16. J Cancer Res Clin Oncol. 2011. PMID: 20552223

10

Korean ethnicity as compared with white ethnicity is an independent favorable prognostic factor for overall survival in non-small cell lung cancer before and after the oral epidermal growth factor receptor tyrosine kinase inhibitor era.

Ahn MJ, Lee J, Park YH, Ahn JS, Ziogas A, Zell JA, Park K, Ou SH. Ahn MJ, et al. Among authors: ahn js. J Thorac Oncol. 2010 Aug;5(8):1185-96. doi: 10.1097/JTO.0b013e3181e2f624. J Thorac Oncol. 2010. PMID: 20592628 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

764 results

Search Page

Filters